Abstract
A new family of dinucleotide derivatives, diinosine polyphosphates, has been synthesized through the use of the enzyme 5′ adenylic acid deaminase from Aspergillus sp., starting from the corresponding diadenosine polyphosphates. Functional studies were performed on rat brain synaptic terminals in which a dinucleotide receptor has been described that is specific for adenine dinucleotides. The results demonstrated that diinosine polyphosphates did not behave as agonists on the diadenosine polyphosphate receptor (also know as P4 purinoceptor), but they were very efficient as antagonists in abolishing the Ca2+ responses elicited by diadenosine pentaphosphate. The IC50 values for diinosine triphosphate, diinosine tetraphosphate, and diinosine pentaphosphate were 4.90 ± 0.10 μm, 8.33 ± 0.22 μm, and 4.23 ± 0.12 nm, respectively. The diinosine polyphosphates also antagonized the ATP receptors present in synaptic terminals, showing IC50values of 100.08 ± 5.72 μm for diinosine triphosphate, 29.51 ± 1.40 μm for diinosine tetraphosphate and 27.75 ± 1.65 μm for diinosine pentaphosphate. The antagonistic ability of these diinosine nucleotides was studied in comparison with other P1 and P2 purinoceptor antagonists, such as suramin, pyridoxalphosphate-6-azophenyl-2′,4′-disulfonic acid, and 8-cyclopentyl-1,3-dipropylxanthine. These purinergic antagonists did not inhibit the response of the P4 purinoceptor; only the diinosine polyphosphates were able to act as antagonists on the dinucleotide receptor. Suramin and pyridoxalphosphate-6-azophenyl-2′,4′-disulfonic acid attenuated the responses elicited by ATP, as did the diinosine polyphosphate compounds. The most antagonistic diinosine polyphosphate for the dinucleotide and ATP receptors was diinosine pentaphosphate, which was 6000 times more selective for the P4 purinoceptor than it was for the ATP receptor.
Footnotes
- Received August 7, 1996.
- Accepted October 18, 1996.
-
Send reprint requests to: Dr. Jesús Pintor, Dep. Bioquimica, Facultad de Veterinaria, Universidad Complutense, 28040 Madrid, Spain. E-mail: mtmiras{at}eucmax.sim.ucm.es
-
This work was supported by grants from the Fundación Areces Neuroscience and the European Union BIOMED2 (PL950676) and Spanish Dirección General de Investigación Cientı́fica y Tecnológica (PB 95/72). J.G. has a fellowship from the Comunidad Autónoma de Madrid.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|